CN102149703B - 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症 - Google Patents

抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症 Download PDF

Info

Publication number
CN102149703B
CN102149703B CN200980135652.3A CN200980135652A CN102149703B CN 102149703 B CN102149703 B CN 102149703B CN 200980135652 A CN200980135652 A CN 200980135652A CN 102149703 B CN102149703 B CN 102149703B
Authority
CN
China
Prior art keywords
compound
dimethylamino
mixture
diazenyl
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980135652.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102149703A (zh
Inventor
G·R·古卡拉吉
S·卡斯娜
R·R·古卡拉吉
T·吉拉考提
V·索门帕利
S·柯瑞莎鲁
K·布湖帕瑟拉吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laila Nutraceuticals
Original Assignee
Laila Nutraceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laila Nutraceuticals filed Critical Laila Nutraceuticals
Publication of CN102149703A publication Critical patent/CN102149703A/zh
Application granted granted Critical
Publication of CN102149703B publication Critical patent/CN102149703B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN200980135652.3A 2008-09-15 2009-09-14 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症 Expired - Fee Related CN102149703B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2230CH2008 2008-09-15
IN2230/CHE/08 2008-09-15
PCT/IN2009/000504 WO2010029577A2 (en) 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Publications (2)

Publication Number Publication Date
CN102149703A CN102149703A (zh) 2011-08-10
CN102149703B true CN102149703B (zh) 2014-09-10

Family

ID=41565903

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980135652.3A Expired - Fee Related CN102149703B (zh) 2008-09-15 2009-09-14 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症

Country Status (11)

Country Link
US (1) US8258119B2 (enExample)
EP (1) EP2324006B1 (enExample)
JP (1) JP2012502900A (enExample)
KR (1) KR20110063537A (enExample)
CN (1) CN102149703B (enExample)
AU (1) AU2009290365B2 (enExample)
BR (1) BRPI0913485A2 (enExample)
CA (1) CA2736732A1 (enExample)
IL (1) IL211366A0 (enExample)
NZ (1) NZ591394A (enExample)
WO (1) WO2010029577A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1006651A2 (pt) * 2009-04-27 2015-08-25 Kasina Laila Innova Pharmaceuticals Private Ltd Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres
NO2686520T3 (enExample) 2011-06-06 2018-03-17
CA2837560C (en) * 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
US9593095B2 (en) 2013-06-14 2017-03-14 Duke University Methods for the treatment of bacterial infections
WO2015197096A1 (en) * 2014-06-27 2015-12-30 Ecole Polytechnique Federale De Lausanne (Epfl) Preparation and medical use of triazenes
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
MX374909B (es) 2015-04-01 2025-03-06 Akebia Therapeutics Inc El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.
EP3297624B1 (en) 2015-05-18 2021-03-03 Syn-Nat Products Enterprise LLC A pharmaceutical co-crystal and use thereof
AU2016279099B2 (en) 2015-06-19 2021-09-23 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
CN108697093A (zh) 2015-06-19 2018-10-23 新纳特产品公司 含卡铂的组合物及其用途
EP3297640A4 (en) 2015-06-25 2019-01-02 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
IL278533B1 (en) 2018-05-09 2025-10-01 Akebia Therapeutics Inc Process for the preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1020641B (de) 1955-10-15 1957-12-12 Basf Ag Verfahren zur Herstellung von Derivaten der 3-Oxythiophen-2-carbonsaeure
CA968347A (en) * 1968-09-09 1975-05-27 John F. Gerster Substituted pyrazoles and process

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis and Cytostatic Activity of 4-Substituted Derivatives of Isoxazolyltriazenes;E. Wagner, et al.;《Polish J. Chem.》;20031231;第77卷(第8期);1001-1006 *
The Chemistry of 1,1-Dithiolates;L. Henriksen, et al.;《ACTA CHEMICA SCANDINAVICA》;19721231;第26卷(第8期);3342-3346 *

Also Published As

Publication number Publication date
EP2324006B1 (en) 2014-08-13
KR20110063537A (ko) 2011-06-10
AU2009290365A1 (en) 2010-03-18
IL211366A0 (en) 2011-04-28
WO2010029577A2 (en) 2010-03-18
JP2012502900A (ja) 2012-02-02
EP2324006A2 (en) 2011-05-25
CA2736732A1 (en) 2010-03-18
WO2010029577A3 (en) 2010-05-06
US8258119B2 (en) 2012-09-04
CN102149703A (zh) 2011-08-10
US20100068178A1 (en) 2010-03-18
AU2009290365B2 (en) 2014-08-14
NZ591394A (en) 2013-03-28
BRPI0913485A2 (pt) 2016-06-07

Similar Documents

Publication Publication Date Title
CN102149703B (zh) 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症
CN102438449B (zh) 抗癌药物及将其用于治疗恶性黑色素瘤及其它癌症
US10315990B2 (en) Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof
US10562912B2 (en) Heterocyclic derivatives and use thereof
US20250059204A1 (en) Fused benzoisoxazolyl compounds as kat6a inhibitors
JP2001525325A (ja) チエノピリミジン類
JP2002513026A (ja) ホスホジエステラーゼｖ阻害作用を有する凝縮チエノピリミジン類
CN114080389B (zh) Nrf2活性化化合物
JP6903266B2 (ja) １，２ナフトキノン誘導体及びその製造方法
HK1154863A (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
WO2009033396A1 (fr) Composés dithiolopyrrolones, leur préparation et leur utilisation
CN102260239B (zh) 胡黄连素衍生物及其制备与应用
CN102600164B (zh) 嘧啶醚类化合物作为制备抗肿瘤药物的应用
CN117321036A (zh) 具有抗癌活性的苯基-o-喹啉、喹唑啉、噻吩并吡啶、噻吩并嘧啶、吡咯并吡啶、吡咯并嘧啶化合物
CN113004222B (zh) 一种氨基二硫代过酸硫酯类化合物及其制备方法和应用
US20250214945A1 (en) Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof, and use thereof
CN107141299A (zh) 一种取代吡咯色原酮类化合物及其应用
CN103570721A (zh) 三唑并吡嗪（酮）以及异噁唑并哌啶酮类化合物
HK1166591B (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
CN106102747A (zh) 释放no的硝基氧基‑色烯结合物
CN107663202A (zh) 3-(脲基-甲基) -4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154863

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140910

Termination date: 20150914

EXPY Termination of patent right or utility model
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1154863

Country of ref document: HK